TY - JOUR
T1 - Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity:
T2 - A case report
AU - Latorre, Agnese
AU - Fioretti, Agnese Maria
AU - Giotta, Francesco
AU - Lorusso, Vito
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.
AB - Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.
KW - cardiological comorbidity
KW - lenvatinib
KW - papillary thyroid cancer
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85071579479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071579479&partnerID=8YFLogxK
U2 - 10.2217/fon-2019-0114
DO - 10.2217/fon-2019-0114
M3 - Article
C2 - 31393171
AN - SCOPUS:85071579479
VL - 15
SP - 27
EP - 33
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 24s
ER -